OU-SCC-TOPSCAR

TopsCAR is a biotechnology company focused on the development of highly potent chimeric antigen receptor (CAR) T-cell therapies for oncology. Spun out from the University of Oklahoma and the Stephenson Cancer Center, the company utilizes its proprietary T-cell Optimized Protein Synthesis (TOPS) platform to enhance the translation efficiency and persistence of CAR molecules. This approach is designed to overcome the common hurdle of T-cell exhaustion, potentially leading to more durable clinical responses in patients with liquid and solid tumors. The company's lead programs are currently in the pre-clinical and IND-enabling stages, targeting well-validated antigens like CD19 as well as novel solid tumor targets.